ImmunityBio announced that the Pharmaceutical Administration Bureau of the Macau Special Administrative Region granted approval for its IL‑15 superagonist ANKTIVA for the treatment of BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ and papillary tumors. The approval, received on March 20 2026, marks the first time an IL‑15 superagonist has been cleared for bladder cancer and extends the drug’s commercial reach beyond the United States, where ANKTIVA already received FDA approval and has been commercially launched.
The Macau clearance is part of ImmunityBio’s reliance‑based regulatory strategy, which uses prior FDA and EMA decisions to accelerate approvals in new markets. By obtaining clearance in Macau, the company can begin sales and distribution in the region, potentially increasing its addressable market and providing a new revenue stream that could help offset the company’s high monthly cash burn of roughly $34 million and its substantial long‑term debt. The approval also positions ImmunityBio to pursue further approvals in other Asian jurisdictions, aligning with its long‑term growth strategy.
Financially, ImmunityBio reported net product revenue of $113 million for 2025, a 700% year‑over‑year increase, and a 750% rise in unit sales volume. Despite this strong performance, the company’s cash balance of $242.8 million as of December 31 2025 and its ongoing burn rate raise concerns about the sustainability of its runway. The Macau approval is therefore a positive development, but it does not eliminate the need for continued capital generation to support the company’s pipeline and operations.
In pre‑market trading, ImmunityBio’s shares were trading modestly higher, reflecting investor optimism around the company’s expanding global regulatory footprint. The approval follows recent successes in the UK, EU (conditional), and Saudi Arabia, and is expected to contribute to the company’s revenue trajectory in the coming quarters.
Patrick Soon‑Shiong, Founder and Executive Chairman, said, “This approval in Macau reflects the strength of the clinical and regulatory foundation supporting ANKTIVA in BCG‑unresponsive NMIBC CIS, with or without papillary tumors.” He added that the company is “enabling global access to an immunotherapy designed to activate NK and T‑cell function and address the underlying immune deficit in bladder cancer.”
The competitive landscape for bladder cancer in Macau and broader Asia includes several established therapies, but ANKTIVA’s unique IL‑15 mechanism offers a distinct therapeutic option. The approval also provides ImmunityBio with a foothold in a market that has limited access to novel immunotherapies, potentially giving the company a first‑mover advantage in the region.
Looking ahead, ImmunityBio plans to pursue additional approvals and label expansions for ANKTIVA, including potential indications in lung cancer. The Macau clearance strengthens the company’s global strategy and may accelerate future regulatory submissions, but the company must continue to manage its cash burn and debt to sustain long‑term growth.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.